sicklecellanemianews46m
Most patients free of vaso-occlusive crises for years after Casgevy dose
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
sicklecellanemianews1d
The difficult reality of dealing with invisible sickle cell complications
Invisible complications of sickle cell disease can result in a lack of understanding and proper care, says columnist.
sicklecellanemianews2d
Most SCD patients given Lyfgenia in trials stay free of VOEs: New data
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...
sicklecellanemianews7d
Kanglin raises $20M to advance sickle cell gene therapy KL003
Kanglin Biotechnology has raised $20 million in financing to advance the development of KL003, an experimental gene therapy for sickle cell disease (SCD) and beta thalassemia. The China-based company ...